Brief: Spectrum Pharma Reports Q4 2021 And FY 2021 Financial Results
17/03/2022 20:01
March 17 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2021 AND
FULL
YEAR 2021 FINANCIAL RESULTS AND CORPORATE UPDATE
* Q4 NON-GAAP LOSS PER SHARE $0.17
* Q4 LOSS PER SHARE $0.26
* ADDITIONAL CASH, COMBINED WITH RESTRUCTURING, IS EXPECTED
TO
EXTEND CO'S CASH RUNWAY INTO 2023
* Q4 EARNINGS PER SHARE VIEW $-0.21 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw1Jn4D3a
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary